English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NA /

CDA5050/0006

Phase 1 Open-Label Study With A Novel Triple Mechanism Of Action IP In Combination With Pembrolizumab For Advanced Malignancies.

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: